Oxidized LDL and LOX-1 in Experimental SepsisReport as inadecuate

Oxidized LDL and LOX-1 in Experimental Sepsis - Download this document for free, or read online. Document in PDF available to download.

Mediators of InflammationVolume 2013 2013, Article ID 761789, 6 pages

Review Article

Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University Halifax, Nova Scotia, Canada B3H 2Y9

Department of Pharmacology, Dalhousie University Halifax, Nova Scotia, Canada B3H 2Y9

Department of Microbiology and Immunology, Dalhousie University Halifax, Nova Scotia, Canada B3H 2Y9

Department of Anesthesiology and Operative Intensive Care Medicine, Charité, Universitätsmedizin, Berlin, Germany

Received 23 May 2013; Accepted 13 July 2013

Academic Editor: Asım Orem

Copyright © 2013 Nadia Al-Banna and Christian Lehmann. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Oxidized low-density lipoproteins oxLDL and the lectin-like oxLDL receptor-1 LOX-1 are upregulated in inflammation. Because of the importance of inflammation and capillary leakage in the impairment of the microcirculation, which in turn contributes to the development of sepsis and multiorgan failure, the role of oxidized LDL and LOX-1 as players of intestinal inflammation is of great interest. In fact, the blockade of LOX-1 during experimental endotoxemia was effective in reducing leukocyte activation. There are several mechanisms by which oxLDL can participate in local and systemic inflammation, including cell proliferation, apoptosis, capillary perfusion, leukocyte-endothelial cell interactions, and endothelial activation. This review highlights the evidence relating oxLDL and LOX-1 to proinflammatory disease mechanisms. We also indicate situations when oxLDL, because of exposure time, dose, or degree of oxidization, is involved in disease resolution. Modulation of LOX-1 response could be utilized for the treatment of local and systemic inflammation, but the successful use of this target requires further understanding of its broad effects.

Author: Nadia Al-Banna and Christian Lehmann

Source: https://www.hindawi.com/


Related documents